However, glucagon-like peptide-1 receptor agonists (GLP-1 RA), typically used in the treatment of T2D, have been considered as an off-label PCOS therapy for women who do not have T2DM [7]. This evidence concerns the gene GLP1R and polycystic ovary syndrome.